中
繁
EN
Search form
Search this site
For Patients
Investors
Careers
Contact
Home
About Us
Our Story
Leadership
Board of Directors
Jacobio people stories
Platform & Pipeline
Platform
Pipeline
Publications
Partnership
News
Company News
Media Report
Company News
75
press releases in total
Year
-Year
2025
2024
2023
2022
2021
2020
2019
2018
2024
May 10, 2024
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of KRAS G12C Inhibitor Glecirasib in Patients with Colorectal Cancer
[More]
May 6, 2024
Jacobio Announces the Submission of New Drug Application for Glecirasib
[More]
May 1, 2024
Jacobio Pharma Announced its KRAS G12C Inhibitor Reached the Primary Endpoint
[More]
Apr 26, 2024
Jacobio Pharma to Announce Two Oral Presentation at 2024 ASCO
[More]
Apr 17, 2024
Jacobio Receives Orphan Drug Designations for Glecirasib for Pancreatic Cancer in the U.S.
[More]
Apr 9, 2024
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
[More]
Mar 28, 2024
Jacobio Pharma Announces 2023 Annual Results
[More]
Mar 1, 2024
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30355 in the U.S.
[More]
Feb 18, 2024
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
[More]
Jan 20, 2024
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
[More]
2023
Dec 7, 2023
Jacobio Pharma to Present Data of KRAS G12C Inhibitor Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
[More]
Oct 27, 2023
Jacobio Completes First Patient Dosage of Glecirasib in a Pivotal Clinical Trial for the Treatment of Pancreatic Cancer in China
[More]
Oct 22, 2023
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO
[More]
Aug 30, 2023
Jacobio Pharma Announces 2023 Interim Results
[More]
Aug 7, 2023
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer
[More]
Jul 21, 2023
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference
[More]
Jul 4, 2023
Jacobio Receives CDE Approval for Glecirasib’s Pancreatic Cancer Pivotal Study in China
[More]
Jun 29, 2023
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer
[More]
Jun 8, 2023
Jacobio Pharma Receives IND Approval for PARP7 Inhibitor JAB-26766 in China
[More]
Apr 18, 2023
Jacobio Pharma Presented Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
[More]
Pages
«
‹
1
2
3
4
›
»
京公网安备 11030102011242号